## IR: Ingersoll Rand Inc. - XLI: Industrials

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($78.68)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Lab automation specialist Scinomix joins Ingersoll Rand’s life sciences arm**
- Source: Stock Titan | 20260105T213157 | Somewhat-Bullish | Relevance: 100%
- Ingersoll Rand (NYSE: IR) has acquired Scinomix, a U.S.-based designer and manufacturer of lab automation technologies, to expand its life sciences portfolio. This acquisition integrates Scinomix into Ingersoll Rand's Precision and Science Technologies Life Sciences platform, aiming to provide comprehensive, end-to-end solutions for sample management and lab equipment automation. The deal was made at an attractive pre-synergy multiple of approximately 10x 2025 Adjusted EBITDA.

**2. Ingersoll Rand acquires lab automation firm Scinomix**
- Source: Investing.com India | 20260105T223203 | Bullish | Relevance: 100%
- Ingersoll Rand (NYSE:IR) has acquired Scinomix, Inc., a U.S.-based manufacturer of laboratory automation technologies, expanding its life sciences portfolio. The acquisition is expected to combine Ingersoll Rand’s existing technologies with Scinomix’s offerings to provide comprehensive solutions for laboratory environments, aligning with Ingersoll Rand's growth strategy. This strategic move follows Ingersoll Rand's impressive financial performance and recent acquisitions like Transvac Systems Ltd., along with the appointment of Jerome Guillen to its Board of Directors.

**3. 13,246 Shares in Ingersoll Rand Inc. $IR Purchased by Ascent Group LLC**
- Source: MarketBeat | 20260103T080820 | Neutral | Relevance: 100%
- Ascent Group LLC has acquired a new stake of 13,246 shares in Ingersoll Rand Inc. (NYSE:IR), valued at approximately $1.094 million, during the third quarter. Wall Street analysts currently rate Ingersoll Rand as a "Hold" with a consensus target price of $91.44, though recent price target adjustments have been mixed. Insider activity includes Chief Accounting Officer Michael J. Scheske selling 1,477 shares in December, reducing his holdings by 10.84%.

**4. Ingersoll Rand Expands Life Sciences Portfolio with Acquisition of Scinomix, Inc.**
- Source: Quiver Quantitative | 20260105T214457 | Bullish | Relevance: 97%
- Ingersoll Rand Inc. has acquired Scinomix, Inc., a U.S.-based company specializing in automation technologies for life sciences, to enhance its portfolio and growth strategy. This acquisition aims to improve workflow automation, efficiency, and accuracy for customers in clinical and pharmaceutical labs. Ingersoll Rand expects to offer comprehensive end-to-end solutions by integrating Scinomix's innovations and acquired the company at an attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Stifel | $81 | $75 | +8% |
| 2025-12-08 | Citigroup | $94 | $91 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Stifel | main | Hold |
| 2025-12-08 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 66.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Capital Internationa: 12.7% (+18.5%)
- Vanguard Group Inc: 11.5% (-3.7%)
- Capital World Invest: 8.1% (+19.2%)
- Blackrock Inc.: 7.5% (-6.7%)
- JPMORGAN CHASE & CO: 6.3% (+36.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- M&A activity or partnership announcements may unlock value.
- Momentum building: MRS_20 improving +1.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 23.1x stretched relative to 9% growth. Balance sheet: strong liquidity (2.2x). Analyst sentiment positive (2 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $32.7B |
| Beta | 1.33 |
| 52W Range | $65.61 - $95.85 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 23.1 |
| Current P/E | 25.0 |
| YoY Growth | 8.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.4% to 2.0% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.0pp (needs >4.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.02% (CS: 63) | Neutral |
| RSI_14 | 58.6 | Neutral |
| MACD Histogram | -0.03 | Bearish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.028x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $82.20
- **Stop Loss:** $78.68 (4.3% risk)
- **Target:** $89.24 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 392
- **Position Value:** $32,222.40
- **Portfolio %:** 32.22%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $0.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.86 | $0.86 | -0.3% |
| 2025Q2 | $0.80 | $0.80 | +0.2% |
| 2025Q1 | $0.74 | $0.72 | -2.3% |
| 2024Q4 | $0.84 | $0.84 | -0.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*